我国实施抗体偶联药物分段生产的风险分析及监管对策思考

我国实施抗体偶联药物分段生产的风险分析及监管对策思考

China Food Drug Administration ›› 2025, Vol. 0 ›› Issue (5) : 52-59.

PDF(1577 KB)

PDF(1577 KB)

China Food Drug Administration ›› 2025, Vol. 0 ›› Issue (5) : 52-59. DOI: 10.3969/j.issn.1673-5390.2025.05.005

{{article.zuoZhe_EN}}

Author information +

History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

Download Citations

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}

{{article.copyrightLicense_en}}

PDF(1577 KB)

Accesses

Citation

Detail

Sections

Recommended

/

〈

〉